Chronic Lymphocytic Leukemia — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:
• Introduction (0:00)
• Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22)
• Available and Emerging Approaches to Time-Limited Therapy for Treatment-Naïve CLL — Dr Allan (23:24)
• Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Dr Ma (56:31)
• Selection and Sequencing of Therapy for Relapsed/Refractory CLL — Dr Shadman (1:17:01)
• Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — Dr Abramson (1:38:24)

CME information and select publications (researchtopractice.com/ASCO2026/CLL/Video)